Alpha Score of 71 reflects strong overall profile with strong momentum, moderate value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Eli Lilly (LLY) moved higher today, driven by robust earnings momentum and quality metrics. The stock, trading near the top of its 52-week range ($625.65-$1109.94), reflects a 47.4% revenue surge and a 128.8% EPS jump year over year. Net margin stands at a healthy 35.0%, underscoring operational efficiency. LLY's Alpha Score of 71.2 is supported by a momentum sub-score of 88.6 and a quality sub-score of 87, though value remains moderate at 60. With a P/E of 44.08, the market prices in continued high growth. Forward watch: Next week, focus on any updates to pipeline catalysts or guidance, as these will test whether the current valuation can sustain.
LLY remains elevated near the upper end of its 52W range, supported by exceptional fundamental momentum. Revenue growth of 47.4% YoY and a 128.8% EPS surge reflect strong demand for its key products. The net margin of 35.0% underscores operational efficiency. Alpha Score of 69.1 is driven by a momentum subscore of 82.4 and quality at 87, while value at 60 reflects the premium valuation: P/E of 44.08 on trailing EPS of 22.8. Sentiment data is not available. With the stock trading near its 52W high, investors are pricing in sustained growth. Forward watch: Next quarterly results and updates on pipeline catalysts will determine if the momentum can be maintained.
Eli Lilly shares moved higher today, supported by robust fundamental momentum and quality scores. The stock trades at a P/E of 44.08, reflecting premium valuation justified by exceptional 47.4% revenue growth and 128.8% EPS growth year over year. Net margin stands at 35.0%, underscoring operational efficiency. The Alpha Score of 70.3 is driven by momentum at 85.9 and quality at 87, while value scores a moderate 60. The stock sits near the top of its 52 week range at $1109.94, suggesting strong price momentum. Investors are rewarding Lilly's pipeline progress and earnings acceleration. Forward watch: next week, watch for any clinical trial updates or regulatory decisions that could sustain or challenge this growth trajectory.
Eli Lilly shares remain supported near the top of their 52-week range ($625.65-$1109.94), underpinned by exceptional earnings momentum and robust quality metrics. Revenue grew 47.4% year over year, while EPS surged 128.8%, driving a net margin of 35.0%. The stock carries a P/E of 44.08, reflecting premium valuation consistent with its growth trajectory. Alpha Score of 67.3 is driven by a momentum sub-score of 76.9 and quality at 87, with value at 60 and sentiment not reported. The combination of high profitability and accelerating earnings continues to attract investors in the healthcare sector. Next week, watch for any updates on pipeline catalysts or competitor moves in the GLP-1 market that could shift sentiment.
Eli Lilly traded near the top of its 52-week range ($625.65-$1109.94) as investors continued to price in exceptional operational momentum. The stock's Alpha Score of 70.4 reflects robust quality (87) and momentum (78.9) sub-scores, offset by a neutral sentiment reading (50). Revenue surged 47.4% year-over-year, while EPS growth accelerated to 128.8%, driving the net margin to 35.0%. The P/E of 44.08 remains elevated relative to the broader market, but the combination of high growth and strong margins supports the premium. Value scores a below-average 60, indicating limited upside from valuation alone. With no company-specific news today, the stock's stability suggests the market is consolidating after a strong run. Forward watch: next week's industry conference may provide updates on pipeline candidates, particularly in obesity and Alzheimer's, which could influence near-term sentiment.
Eli Lilly and Company filed its 10-K for the fiscal year ended December 31, 2025. The filing details the company's financial position, including its debt structure with various notes maturing between 2026 and 2061. The company maintains significant product concentration in its cardiometabolic, oncology, immunology, and neuroscience segments. Key products highlighted include Mounjaro, Zepbound, Trulicity, Jardiance, Verzenio, and Taltz. The company reports customer concentration risk related to its three largest wholesalers. The filing also outlines recent corporate activity, including investments and acquisitions involving Verve Therapeutics, SiteOne Therapeutics, Scorpion Therapeutics, Morphic Holding, and others. The company continues to manage its portfolio through divestitures, such as the previous sale of the Olanzapine portfolio and Baqsimi. Financial disclosures include fair value measurements for marketable securities and debt instruments.
Eli Lilly and Company filed a Form 8-K on February 4, 2026, to formally announce its financial results for the quarter and the full fiscal year ended December 31, 2025. The filing serves as a procedural notification regarding the release of the company's earnings performance. The actual financial data, including revenue, earnings per share, and management commentary, is contained within Exhibit 99.1, which is a press release issued by the company on the same date. Per the filing, the information provided under Item 2.02 is furnished and not deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934. This means the information is not subject to the liabilities of that section and is not incorporated by reference into other registration statements or documents filed under the Securities Act of 1933 or the Exchange Act, unless explicitly stated otherwise by the company in future filings.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 5.02M | $5.40B | NEW |
| Marshall Wace | 1.31M | $1.41B | NEW |
| D.E. Shaw David Shaw | 1.17M | $1.26B | NEW |
| Point72 Steve Cohen | 184K | $197.58M | NEW |
| Renaissance Technologies Jim Simons (founder) | 166K | $178.23M | NEW |
| Soros Fund Management George Soros (founder) | 22K | $24.00M | NEW |
| ARK Invest Cathie Wood | 13K | $11.66M | NEW |
Eli Lilly and Company is a leading pharmaceutical company engaged in the discovery, development, manufacture, and sale of human pharmaceutical products. It focuses on innovative medicines addressing critical health needs in areas such as diabetes, oncology, immunology, neuroscience, obesity, cardiovascular diseases, cancer, and other therapeutic categories including bone muscle joint disorders, endocrine conditions, dermatology, autoimmune diseases, sleep apnea, migraine, and Alzheimer's disease. The company offers treatments like insulins, GLP-1 therapies for diabetes and obesity, oncology drugs, immunologic agents, and neuroscience products. Eli Lilly and Company supports access initiatives through partnerships for technology transfer and API supply to manufacturers in low- and middle-income countries, enhancing availability of insulins and other therapies in regions like Africa and Bangladesh. It maintains a robust research and development pipeline targeting non-communicable diseases, with late-stage projects in diabetes, cardiovascular, and oncology areas. Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company plays a significant role in the global health technology sector by delivering therapies that improve patient outcomes across diverse medical fields.
Earnings calendar coming soon. Subscribe to get notified when LLY reports next.
Get earnings alerts →